Lung Cancer

Continuing treatment with zenocutuzumab beyond disease progression was effective and safe in patients with advanced NRG1+ NSCLC.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in February 2026 spanning tumor types.

Eric K. Singhi, MD, discusses where TROP2-directed ADCs like datopotamab deruxtecan and sacituzumab tirumotecan may fit in evolving treatment algorithms in lung cancer.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in February 2026.

The top 5 OncLive TV videos of the week cover insights in lung cancer, renal cell carcinoma, prostate cancer, head and neck cancer, and multiple myeloma.

The FDA has granted accelerated approval to zongertinib in HER2 TKD–mutated NSCLC, full approval to an encorafenib combination in BRAF V600E+ mCRC, and more.

Anne Chiang, MD, PhD, discusses the rapidly evolving treatment landscape in SCLC and what this new era of innovation means for patients.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

David Carbone, MD, PhD, discusses the 6-year data from the phase 3 CheckMate 9LA trial (NCT03215706).

Balazs Halmos, MD, MS, highlights the significance of the accelerated approval of zongertinib in HER2 TKD–mutated non–small cell lung cancer.

The FDA expanded the indication for zongertinib in unresectble or metastatic nonsquamous NSCLC harboring HER2 TKD mutations.

The FDA approved a frontline acalabrutinib regimen in CLL/SLL and a simplified dosing schedule for Rybrevant Faspro in EGFR+ NSCLC and will review NDAs in PCNSL and breast cancer.

Alexander I. Spira, MD, PhD, FACP, FASCO, discusses the FDA approval of subcutaneous amivantamab for patients with EGFR-mutated NSCLC.

The FDA approved a monthly dosing schedule of amivantamab and hyaluronidase for the first-line treatment of patients with EGFR-mutated, advanced NSCLC.

Improved EFS was seen when selpercatinib was administered as adjuvant therapy vs placebo in early-stage RET fusion–positive NSCLC.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in January 2025 spanning tumor types.

Data from the phase 3 LU005 trial found no OS benefit and high immune-related toxicity with concurrent/adjuvant atezolizumab and chemoradiation in LS-SCLC.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in January 2026.

The American Cancer Society has released their annual Cancer Facts & Figures and Cancer Statistics reports.

Xiuning Le, MD, PhD, discusses the mechanism of action of sevabertinib in HER2-mutated NSCLC.

The FDA has approved Darzalex Faspro plus VRd for select multiple myeloma and several applications are under regulatory review in lung and GI cancers.

Adam Fox, MD, and Cynthia A. Schandl, MD, PhD, examined the expanding role of biomarker testing and genomic profiling in NSCLC across disease stages.

OncLive spoke to 4 experts in order to unpack the top data presented during oncology conferences over the course of 2025.

The FDA has accepted a BLA seeking the approval of ivonescimab plus chemotherapy for EGFR-mutated, advanced, nonsquamous NSCLC after TKI progression.

Enriqueta Felip, MD, PhD, discusses key efficacy data from the MARIPOSA trial and its implications.